Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis

Acta Oncol. 1988;27(6b):823-4. doi: 10.3109/02841868809094366.

Abstract

In a pilot study 12 patients with radically resected inguinal lymph node metastases from carcinoma of the penis and 5 patients with fixed inguinal nodes were treated with 12 weekly courses of vincristine, bleomycin and methotrexate (VBM). Only 1 of the 12 cases treated with adjuvant VBM relapsed after a median follow-up period of 42 months (range 18-102 months). Three partial responders to neoadjuvant VBM could have radical lymphadenectomy and they are alive disease-free 20, 27, 72 months after surgery. Two minimal responders could not have radical surgery and they died of the disease within one year.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / adverse effects
  • Bleomycin / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy*
  • Humans
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Male
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use
  • Middle Aged
  • Penile Neoplasms / drug therapy*
  • Pilot Projects
  • Vincristine / adverse effects
  • Vincristine / therapeutic use

Substances

  • Bleomycin
  • Vincristine
  • Methotrexate

Supplementary concepts

  • VBM protocol